Codexis, Inc. (CDXS)
NMS · Healthcare · Biotechnology
$2.40
-0.41%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$218.2M
Shares Outstanding
90.9M
P/S (TTM)
2.8x
Exchange
NMS
Currency
USD
About Codexis, Inc.
Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 15.3M | 8.6M | 38.9M | 15.2M |
| Gross Profit | 13.2M | 6.1M | 36.9M | 13.2M |
| Operating Income | -12.9M | -18.9M | 14.0M | -8.0M |
| Net Income | -13.3M | -19.6M | 9.6M | -8.7M |
| Diluted EPS | $-0.16 | $-0.22 | $0.11 | $-0.10 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 138.6M | 70.1M | 59.3M | 70.4M |
| Gross Profit | 100.6M | 57.3M | 43.1M | 61.0M |
| Operating Income | -31.7M | -54.8M | -58.4M | -38.3M |
| Net Income | -33.6M | -76.2M | -65.3M | -44.0M |
| Diluted EPS | $-0.51 | $-1.12 | $-0.89 | $nan |